Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 18, 2024 05:09 ET | Source: Research and Markets

Global Fibrate Drugs Market 10 Year Forecast Report 2024-2034, by Drug Type, by Product Type, by Distribution Channel and By Region

Dublin, March 18, 2024 (GLOBE NEWSWIRE) -- The "Global Fibrate Drugs Market by Drug Type, by Product Type, by Distribution Channel, and By Region" report has been added to ResearchAndMarkets.com's...
January 25, 2024 06:15 ET | Source: Research and Markets

Statins Market Analysis Reveals Robust Growth Prospects with Rising Demand for Cardiovascular Solutions

Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Statins Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user,...
January 24, 2024 10:32 ET | Source: Research and Markets

Atherosclerotic Cardiovascular Disease Market Set to Exhibit Growth by 2032, Driven by Advancements and Emerging Therapies

Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Atherosclerotic Cardiovascular Disease (ASCVD) - Market Insight, Epidemiology And Market Forecast - 2032" report has been added to ...
June 04, 2020 07:00 ET | Source: Esperion Therapeutics, Inc.

Esperion Announces Commercial Availability of NEXLIZET™ (bempedoic acid and ezetimibe) Tablets and Ushers in New Era of Oral Combination Medicine for LDL-Cholesterol Lowering

– First-Ever Non-Statin Combination Medicine, Providing 38 Percent Mean LDL-C Lowering – – Esperion Aims to Set New Industry Standard by Pricing NEXLIZET for Patient Affordability and Access with...
June 26, 2017 16:05 ET | Source: Esperion Therapeutics, Inc.

Esperion Announces FDA Confirmation of Regulatory Pathway to Approval for the Combination of Bempedoic Acid and Ezetimibe

– Complementary, Non-statin, Oral Bempedoic Acid / Ezetimibe Combination Therapy Demonstrates 48% Lowering of LDL-C and Significant hsCRP Reduction with Potential for Lower Occurrence of...